Hyperimmune immunoglobulin from human plasma showed no clear difference in all‐cause mortality at day 28 compared with saline placebo (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in improvement of clinical status (number of participants discharged… compared with saline placebo (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… led to higher adverse events at grade 3 or 4 (by day 28) compared with saline placebo; GRADE not reported.
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
It is very uncertain whether hyperimmune immunoglobulin from human plasma changes worsening of clinical status at day 28 (data only available for… compared with saline placebo (very low certainty).
Hyperimmune immunoglobulin from human plasma showed no clear difference in adverse events of any grade up to 28 days (data only available for… compared with saline placebo (low certainty).
Hyperimmune immunoglobulin from human plasma probably leads to higher adverse events at grades 3 to 4 up to 28 days compared with saline placebo (moderate certainty).
Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in all‐cause mortality (by day 28) compared with saline placebo (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in worsening of clinical status (expressed as new need for IMV,… compared with saline placebo (low certainty).
Obesity Class II probably leads to higher hospitalisation(30‐days, community) compared with normal Weight or Non‐Obese (moderate certainty).
Obesity Class III may leads to higher hospitalisation (adjusted for DM, HTN, cardiovascular disease, age,… compared with normal BMI, Non‐obese, or BMI < 40 (low certainty).
Obesity (Unclassified) probably leads to higher hospitalisation (adjusted for age, sex, DM, HTN, and cardiovascular… compared with normal Weight or Non‐Obese (moderate certainty).
Obesity (Unclassified) leads to higher severe COVID(30‐days, community) compared with normal Weight or Non‐Obese (high certainty).
Obesity (Unclassified) probably leads to higher pneumonia(30‐days, community) compared with normal Weight or Non‐Obese (moderate certainty).
Obesity (Unclassified) may leads to higher hospitalisation (30 days, community) compared with normal Weight or Non‐Obese (low certainty).
Every 5 units (kg/m2) increase in BMI may leads to higher hospitalisation(30 days, community) compared with N/A (low certainty).
Obesity Class I probably leads to lower hospitalisation(30‐days, community) compared with normal Weight or Non‐Obese (moderate certainty).
It is very uncertain whether the intervention changes anthropometric recovery Defined as: WHZ ≥ −1.5 or MUAC > 125 mm for… (very low certainty).